

## CLINICAL UPDATE

<b>Brand Name</b>	Xtandi®
<b>Generic Name</b>	enzalutamide
<b>Drug Manufacturer</b>	Astellas Pharma US, Inc.

### Clinical Update

#### TYPE OF CLINICAL UPDATE

New Strength and Dosage Form (40 mg, 80 mg, oral tablet)

#### FDA APPROVAL DATE

August 04, 2020

#### LAUNCH DATE

March 01, 2021

#### REVIEW DESIGNATION

Standard

#### TYPE OF REVIEW

Type 3 - New Dosage Form, New Drug Application (NDA): 213674

#### DISPENSING RESTRICTIONS

Specialty

### Overview

#### INDICATION(S) FOR USE

Xtandi® is an androgen receptor inhibitor indicated for the treatment of patients with:

- Castration-resistant prostate cancer.
- Metastatic castration-sensitive prostate cancer.

#### MECHANISMS OF ACTION

Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. It has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.

#### DOSAGE FORM(S) AND STRENGTH(S)

- Oral capsule: 40 mg
- Oral tablet: 40 mg, 80 mg

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

## CLINICAL UPDATE

### DOSE & ADMINISTRATION

160 mg (two 80 mg tablets or four 40 mg tablets or four 40 mg capsules) administered orally once daily. Swallow capsules or tablets whole.

Patients receiving Xtandi® should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

### EFFICACY

The steady-state pharmacokinetic profiles (AUC and C<sub>max</sub>) and efficacy profiles of enzalutamide and N-desmethyl enzalutamide are similar for Xtandi® tablet and Xtandi® capsule.